For a patient with peripheral arterial disease, should cilostazol be used instead of clopidogrel, and is it recommended as monotherapy or in combination with clopidogrel?

Cilostazol Should Not Replace Clopidogrel as Primary Antiplatelet Therapy in PAD

For patients with peripheral arterial disease, clopidogrel (or aspirin) should be the foundation of antiplatelet therapy, not cilostazol. Cilostazol is reserved as an add-on therapy specifically for patients with refractory intermittent claudication despite exercise therapy and smoking cessation.

Primary Antiplatelet Therapy: Clopidogrel or Aspirin

Single antiplatelet therapy with either aspirin (75-100 mg daily) or clopidogrel (75 mg daily) is the Grade 1A recommendation for all patients with symptomatic PAD 1. The 2024 ESC guidelines 2 and 2024 ACC/AHA guidelines 3 both reinforce this approach. Clopidogrel is FDA-approved for reducing MI and stroke in patients with established peripheral arterial disease 4.

The evidence shows:

• Clopidogrel monotherapy demonstrated superior efficacy compared to aspirin in the CAPRIE trial for preventing major adverse cardiovascular events 3
• A 2026 network meta-analysis found clopidogrel monotherapy had the most favorable benefit-harm profile (79% cumulative rank probability best, 77% cumulative rank probability safest) 5
• Clopidogrel reduced major adverse cardiac events with a hazard ratio of 0.72 compared to placebo 6

Cilostazol's Limited Role: Add-On for Refractory Claudication Only

Cilostazol is NOT a replacement for antiplatelet therapy—it serves a completely different purpose. The American College of Chest Physicians guidelines explicitly state: "For patients with intermittent claudication refractory to exercise therapy (and smoking cessation), we suggest the use of cilostazol in addition to previously recommended antithrombotic therapies (aspirin 75-100 mg daily or clopidogrel 75 mg daily) (Grade 2C)" 1.

Key points about cilostazol:

• Cilostazol (100 mg twice daily) is added to—not substituted for—baseline antiplatelet therapy 1
• Its primary benefit is symptomatic relief of claudication (improving walking distance), not cardiovascular event prevention 7, 8
• It should only be considered after failure of exercise therapy and smoking cessation 1
• The recommendation grade is 2C (weak evidence), compared to Grade 1A for clopidogrel/aspirin 1

Dual Therapy: When to Consider Cilostazol Plus Clopidogrel

The combination of clopidogrel plus cilostazol may be beneficial in specific scenarios:

For refractory claudication in diabetic patients:

• A 2021 RCT showed that adding cilostazol to clopidogrel in diabetic patients with symptomatic PAD reduced ischemic vascular events (HR 0.468) and improved ankle-brachial index and pain-free walking distance, without increasing bleeding risk 9

After revascularization procedures:

• Cilostazol added to antiplatelet therapy may reduce restenosis rates and improve limb salvage after endovascular interventions 10, 11
• A 2024 study found cilostazol use associated with lower long-term mortality (11.5% vs 13.4%) and major amputation rates (4.0% vs 4.7%) after peripheral vascular interventions 11

Dual Antiplatelet Therapy: Clopidogrel Plus Aspirin

Dual antiplatelet therapy with aspirin plus clopidogrel is generally NOT recommended for routine PAD management 1. The guidelines suggest against dual antiplatelet therapy (Grade 2B) 1.

Exceptions where dual antiplatelet therapy may be considered:

• 1-3 months after endovascular revascularization in patients without high bleeding risk 2
• Below-knee bypass with prosthetic grafts for 1 year (Grade 2C) 1
• High-risk patients (previous amputation, CLTI, prior revascularization, heart failure, diabetes, multivessel disease, eGFR <60) may benefit from aspirin plus low-dose rivaroxaban 2.5 mg twice daily (Grade IIa) 2, 3

Clinical Algorithm

Step 1: Establish baseline antiplatelet therapy

• Start clopidogrel 75 mg daily OR aspirin 75-100 mg daily
• Clopidogrel preferred based on superior efficacy profile 5, 6

Step 2: Optimize lifestyle modifications

• Supervised exercise therapy
• Smoking cessation
• Lipid management with statins
• Blood pressure and diabetes control

Step 3: Assess for refractory claudication

• If claudication persists despite 3-6 months of exercise therapy and lifestyle modification
• ADD cilostazol 100 mg twice daily to existing antiplatelet therapy
• Do NOT substitute cilostazol for clopidogrel

Step 4: Post-revascularization considerations

• Continue baseline antiplatelet therapy
• Consider short-term (1-3 months) dual antiplatelet therapy after endovascular procedures
• Consider adding cilostazol to reduce restenosis risk

Critical Pitfalls to Avoid

1. Never use cilostazol as monotherapy for PAD—it does not provide adequate cardiovascular protection 1, 12
2. Do not prescribe cilostazol before optimizing exercise therapy—the guidelines are explicit that cilostazol is for refractory claudication 1
3. Avoid cilostazol in patients with heart failure—it is contraindicated due to increased mortality risk in heart failure patients (not mentioned in provided evidence but standard contraindication)
4. Do not continue long-term dual antiplatelet therapy routinely—bleeding risk outweighs benefits except in specific high-risk scenarios 2

Summary Recommendation

Clopidogrel 75 mg daily should be the primary antiplatelet agent for PAD, with cilostazol 100 mg twice daily added only for patients with refractory claudication despite exercise therapy. This approach balances cardiovascular event prevention (clopidogrel's strength) with symptomatic claudication relief (cilostazol's role) while minimizing bleeding risk.